Unknown

Dataset Information

Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors.


ABSTRACT:

Purpose

To develop a population pharmacokinetic (PK) model for cabazitaxel in patients with advanced solid tumors and examine the influence of demographic and baseline parameters.

Methods

One hundred and seventy patients who received cabazitaxel (10-30 mg/m(2), 1-h IV infusion) every 7 or 21 days in five Phase I-III studies were analyzed by non-linear mixed-effect modeling (NONMEM VI). Model evaluation comprised non-parametric bootstrap and visual predictive checks.

Results

Cabazitaxel PK was best described by a linear three-compartment model with: first-order elimination; interindividual variability on clearance (CL), central volume of distribution (V1), and all intercompartmental rate constants except K21; interoccasion variability in CL and V1; proportional residua

SUBMITTER: Ferron GM 

PROVIDER: S-EPMC3579428 | biostudies-literature | 2013 Mar

REPOSITORIES: biostudies-literature